Peeling Skin Syndrome is a rare autosomal disease with no approved treatment or cure Initial clinical site and pediatric patient identified in New Zealand Company actively evaluating opening ...
Target Loadings of 4% and 5% Rapamycin Achieved for Topical Lotion and Dermal Patch Delivery Technologies RespectivelyClinical Trial and ...
ASHBURN, Va., March 25, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late-stage clinical, specialty pharmaceutical company focused on the ...
Quoin Pharmaceuticals Ltd. has filed a U.S. patent application for new topical formulations aimed at treating several skin diseases, specifically Netherton Syndrome (NS) and Peeling Skin Syndrome. The ...
ASHBURN, Va., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”) a clinical stage, specialty pharmaceutical company focused on developing and ...
Target Indications Also Include Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic Dermatitis Third Quoin Patent Application for Netherton Syndrome If Granted Company ...
Company actively evaluating opening additional clinical sites in other countries ASHBURN, Va., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the“Company” or“Quoin”) a ...
Quoin’s innovative pipeline comprises five products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback